Publication Date
1-1-2022
Journal
Vascular Health and Risk Management
DOI
10.2147/VHRM.S275739
PMID
35898405
PMCID
PMC9309324
PubMedCentral® Posted Date
7-20-2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Anticholesteremic Agents, Cardiovascular Diseases, Heart Disease Risk Factors, Humans, PCSK9 Inhibitors, Proprotein Convertase 9, Risk Factors, PCSK9 inhibitor, CVD prevention, lipids
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing low-density lipoprotein cholesterol (LDL-C) and impact on cardiovascular outcomes. Since the approval of commercial use for PCSK9 inhibitors in 2015, we have also gained significant experience in the use of these therapeutics in the real-world setting. In this article, we review current guideline recommendations, clinical trial evidence on efficacy and safety as well as data on cost-effectiveness, prescription and adherence. We focus primarily on the monoclonal antibody class of PCSK9 inhibitors in this review while also touching on other types of therapeutics that are under development.